Literature DB >> 3552864

Possible involvement of an impaired baroreflex mechanism but not the renin-angiotensin system and vasopressin in the enhanced pressor responsiveness to physostigmine in spontaneously hypertensive rats.

K Kawashima, Y Miwa, K Fujimoto.   

Abstract

Effects of physostigmine on heart rate, mean arterial pressure (MAP), plasma renin concentration (PRC) and vasopressin (AVP) release were investigated in spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats. Physostigmine (100 micrograms/kg, i.a.) produced a greater and prolonged hypertensive response in the SHR than in the WKY. Heart rate was increased by physostigmine in SHR rats while it was unchanged in the WKY. PRC was unchanged or even slightly decreased in these animals when MAP was increased by physostigmine. An AVP pressor antagonist did not attenuate the pressor and cardiac effects of physostigmine in these animals. These data indicate that an impaired baroreflex mechanism or a different mode of sympathetic neuronal activation by physostigmine through the central mechanism appears to be contributory, at least in part, to the enhanced pressor responsiveness in the SHR. The renin-angiotensin system and AVP do not appear to be involved in the enhanced pressor responsiveness to physostigmine in SHR rats.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552864     DOI: 10.1016/0306-3623(87)90020-6

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  2 in total

1.  Cardiovascular effects of central injection of acetylcholine in anaesthetized dogs: a role for vasopressin release.

Authors:  O Rascol; J L Montastruc; G Gauquelin; M A Tran; G Geelen; C Gharib; P Montastruc
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

2.  Central cardiovascular effects of acetylcholine in the conscious dog.

Authors:  C Brefel; E Lazartigues; M A Tran; G Gauquelin; G Geelen; C Gharib; J L Montastruc; P Montastruc; O Rascol
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.